협심증 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Angina Pectoris Drugs Market size is expected to reach USD 4.37 Billion in 2034 from USD 2.97 Billion (2025) growing at a CAGR of 4.41% during 2026-2034.

The Global Angina Pectoris Drugs Market is expanding steadily due to the increasing incidence of cardiovascular diseases across the world. Angina pectoris, characterized by chest pain caused by reduced blood flow to the heart, remains a common condition among aging populations and individuals with lifestyle-related risk factors such as obesity, smoking, and hypertension. The growing patient pool requiring long-term cardiovascular management is significantly boosting the demand for effective drug therapies that help alleviate symptoms and improve patient quality of life.

Several factors are driving market growth, including advancements in pharmaceutical research, the development of novel drug formulations, and increased awareness regarding early diagnosis and treatment of heart diseases. Governments and healthcare organizations are also implementing programs aimed at improving cardiovascular health, which further supports the demand for angina medications. In addition, the expanding availability of generic drugs has improved accessibility and affordability, making treatment options available to a broader patient base across both developed and developing regions.

Future prospects for the Global Angina Pectoris Drugs Market remain strong as ongoing research continues to introduce innovative therapies with improved safety and efficacy profiles. Pharmaceutical companies are investing heavily in drug development and clinical trials to address unmet medical needs in cardiovascular care. Furthermore, the growing adoption of personalized medicine and improved healthcare infrastructure in emerging economies are expected to create new opportunities for market expansion. As cardiovascular disease management remains a global priority, the angina pectoris drugs market is anticipated to witness sustained growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Stable Angina
• Unstable Angina
• Microvascular Angina
• Prinzmetal Angina

By Drug Class

• Beta Blockers
• Nitrates
• Anti-Platelets
• Calcium Channel Blockers
• Anticoagulants
• Ace Inhibitors
• Other Drug Classes

By Route Of Administration

• Oral
• Injectable
• Topical

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• AdvaCare Pharma, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim International, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Merck, Novartis, Otsuka Pharmaceutical, Pfizer, Sanofi
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANGINA PECTORIS DRUGS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Stable Angina Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Unstable Angina Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Microvascular Angina Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Prinzmetal Angina Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANGINA PECTORIS DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. Beta Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Nitrates Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Anti-Platelets Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Calcium Channel Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Anticoagulants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Ace Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANGINA PECTORIS DRUGS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANGINA PECTORIS DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANGINA PECTORIS DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Type
  • 8.2.2 By Drug Class
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Type
  • 8.3.2 By Drug Class
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Type
  • 8.4.2 By Drug Class
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Type
  • 8.5.2 By Drug Class
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Type
  • 8.6.2 By Drug Class
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ANGINA PECTORIS DRUGS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 AdvaCare Pharma
  • 10.2.2 Amgen
  • 10.2.3 AstraZeneca
  • 10.2.4 Bayer
  • 10.2.5 Boehringer Ingelheim International
  • 10.2.6 Eli Lilly And Company
  • 10.2.7 Gilead Sciences
  • 10.2.8 GlaxoSmithKline
  • 10.2.9 Merck
  • 10.2.10 Novartis
  • 10.2.11 Otsuka Pharmaceutical
  • 10.2.12 Pfizer
  • 10.2.13 Sanofi